(ACXP) Acurx Pharmaceuticals - Performance -76.6% in 12m
ACXP performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-81.71%
#143 in Peer-Group
Rel. Strength
3.75%
#7387 in Stock-Universe
Total Return 12m
-76.60%
#171 in Peer-Group
Total Return 5y
-93.89%
#140 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | - |
| High / Low | USD |
|---|---|
| 52 Week High | 2.62 USD |
| 52 Week Low | 0.31 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 75.54 |
| Buy/Sell Signal +-5 | -1.29 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: ACXP (-76.6%) vs XBI (-7%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
3.23% | 73% | 77.8% | 22.7 | 13.6 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-9.1% | -6.38% | 147% | 11.3 | 10.5 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
3.91% | -0.97% | 36% | 25.4 | 13.4 | 0.93 | 0.60% | 41% |
| BIM PA Biomerieux |
1.34% | 27.6% | -4.82% | 33.1 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
3.69% | -7.17% | 1.14% | 43 | 24.8 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
18.3% | 43% | -4.19% | 27.6 | 22.4 | 0.9 | 68.9% | 36.8% |
| PTCT NASDAQ PTC Therapeutics |
-4.03% | 58.7% | -9.25% | 7.71 | 6.26 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
6.2% | 28.7% | 15.2% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: ACXP vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for ACXP
| Total Return (including Dividends) | ACXP | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 35.77% | 3.36% | 5.25% |
| 3 Months | 50.62% | 15.73% | 24.13% |
| 12 Months | -76.60% | -7.02% | 14.15% |
| 5 Years | -93.89% | -24.21% | 111.83% |
| Trend Score (consistency of price movement) | ACXP | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 53.4% | 4.4% | 81% |
| 3 Months | 43.8% | 78.8% | 96.9% |
| 12 Months | -93.7% | -85.8% | 44.9% |
| 5 Years | -85.2% | -52.6% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th92.50 | 31.37% | 29.01% |
| 3 Month | %th78.00 | 30.15% | 21.35% |
| 12 Month | %th15.00 | -74.83% | -79.50% |
| 5 Years | %th35.00 | -90.08% | -96.06% |
FAQs
Does Acurx Pharmaceuticals (ACXP) outperform the market?
No,
over the last 12 months ACXP made -76.60%, while its related Sector, the SPDR S&P Biotech (XBI) made -7.02%.
Over the last 3 months ACXP made 50.62%, while XBI made 15.73%.
Performance Comparison ACXP vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
ACXP vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 10.4% | 30.5% | -61.4% | -91% |
| US NASDAQ 100 | QQQ | 10.6% | 30.5% | -62.1% | -89% |
| German DAX 40 | DAX | 12.5% | 37.2% | -73.6% | -105% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 10.6% | 32.5% | -64.9% | -97% |
| Hongkong Hang Seng | HSI | 10.8% | 29.7% | -80.9% | -115% |
| India NIFTY 50 | INDA | 12.2% | 32.3% | -61.8% | -76% |
| Brasil Bovespa | EWZ | 7.9% | 27% | -86.5% | -87% |
ACXP vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 11.8% | 29.9% | -65.6% | -101% |
| Consumer Discretionary | XLY | 10.9% | 32.6% | -53.8% | -94% |
| Consumer Staples | XLP | 10.1% | 35.1% | -63.1% | -85% |
| Energy | XLE | 10.1% | 28.7% | -57.3% | -76% |
| Financial | XLF | 9.7% | 30.7% | -66.4% | -107% |
| Health Care | XLV | 10.9% | 33.6% | -54.1% | -72% |
| Industrial | XLI | 10.3% | 31.6% | -69.3% | -102% |
| Materials | XLB | 8.1% | 31.5% | -66% | -83% |
| Real Estate | XLRE | 10.4% | 34.8% | -61.2% | -89% |
| Technology | XLK | 9.6% | 27.1% | -63.8% | -88% |
| Utilities | XLU | 11.5% | 34% | -64.7% | -100% |
| Aerospace & Defense | XAR | 12.5% | 28.7% | -80% | -126% |
| Biotech | XBI | 9.4% | 32.4% | -48.2% | -70% |
| Homebuilder | XHB | 7.9% | 28.8% | -54.3% | -82% |
| Retail | XRT | 7.9% | 30.8% | -57.1% | -88% |
ACXP vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | 9.5% | 27.3% | -53.1% | -69% |
| Natural Gas | UNG | 19.9% | 45.6% | -44.7% | -74% |
| Gold | GLD | 10.1% | 37% | -82.1% | -116% |
| Silver | SLV | 9.4% | 28.9% | -78.8% | -94% |
| Copper | CPER | 11.3% | 31.2% | -78.5% | -87% |
ACXP vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | 12.2% | 34.7% | -58% | -75% |
| iShares High Yield Corp. Bond | HYG | 11.6% | 34.2% | -60.3% | -87% |